Opioid-free ureteroscopy initiatives appear to be reducing new-persistent opioid use
“This paper shows that our efforts to reduce… opioid exposure in the postoperative setting is reducing new persistent opioid use,” says Matthew S. Lee, MD.
In this video, Matthew S. Lee, MD, discusses the recent Urology paper, “Opioid Free Ureteroscopy: what is the true failure rate?” for which he served as a study author. Lee was an endourology fellow at Indiana University at the time of the study and is currently a clinical instructor at Northwestern University Feinberg School of Medicine.
Dr. Lacouture on managing dermatological adverse events with apalutamide in prostate cancer
February 7th 2022To investigate the severity and prevalence of dermatologic adverse events associated with apalutamide, Mario E. Lacouture, MD, and investigators conducted a study that will help to manage and counsel patients with prostate cancer in the future, especially with the expanded approval of apalutamide in this space.
How appropriate use criteria for PSMA-PET imaging optimize patient care
February 2nd 2022In a recent interview, Hossein Jadvar, MD, PhD, discussed what the appropriate use criteria consist of for prostate-specific membrane antigen (PSMA)-PET imaging, and why these criteria are vital in ensuring the individualized care of patients.
Dr. Padmanabhan discusses impact of COVID-19
June 11th 2020Urology Times® Editorial Council Member Priya Padmanabhan, MD, MPH, professor of urology at Oakland University William Beaumont School of Medicine, Royal Oak, Michigan, discusses how she has been affected by the coronavirus disease 2019 (COVID-19) pandemic.
